Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2025
Distillery Therapeutics
Small molecule inhibitor of KAT8 for esophageal cancer
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Oct 15, 2021
Product Development
Oct. 14 Quick Takes: BeiGene, BMS spar as pharma seeks end to Abraxane deal
Plus: Culture, Anticancer, Rejuvenate, Regeneron and more
BioCentury | Jun 14, 2021
Emerging Company Profile
Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers
Emerging Company Profile: Chengdu-based ACB joins a growing wave of next-gen synthetic lethality companies
BioCentury | Apr 3, 2021
Product Development
Digging beyond the headlines at AACR 2021
Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
Items per page:
1 - 10 of 260